SER 262Alternative Names: SER-262; SER-262 - Designed Ecobiotic®
Latest Information Update: 11 Jul 2016
At a glance
- Originator Seres Therapeutics
- Class Antibacterials; Bacteria
- Mechanism of Action Bacteria replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Clostridium infections
Most Recent Events
- 07 Jul 2016 Phase-I clinical trials in Clostridium infections (Prevention) in USA (PO) (NCT02830542)